-
Product Insights
New![]()
Net Present Value Model: Denali Therapeutics Inc’s DNL-343
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Denali Therapeutics Inc’s DNL-343
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Net Present Value Model: Denali Therapeutics Inc’s DNL-310
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.Drug Operating Profit Model
-
Product Insights
New![]()
Net Present Value Model: Denali Therapeutics Inc’s DNL-151
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Denali Therapeutics Inc’s DNL-788
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Denali National Park Bridge – Alaska
Equip yourself with the essential tools needed to make informed and profitable decisions with our Denali National Park Bridge - Alaska report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the Denali National...
-
Product Insights
Denali Com Ppty/ Epic Games/ Turnbridge Equities – Carolina Yard Mixed-Use Development – North Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Denali Com Ppty/ Epic Games/ Turnbridge Equities - Carolina Yard Mixed-Use Development - North Carolina report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash...
-
Company Profile
![]()
Denali Therapeutics Inc – Company Profile
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. Its proprietary drug delivery platform technologies include an antibody transport vehicle and an enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other...
Add to Basket -
Product Insights
Hines Interests/ LC Fulenwider – Denali Logistics Park – Colorado
Hines Interests/ LC Fulenwider – Denali Logistics Park – Colorado involves the construction of a 2,78,709m2 industrial and logistics park comprising three buildings on 87.41ha of land in Denver, Aurora, the US. The US$250 million project includes the following: 1. Construction of cross-dock 2. Construction of warehouse 3. Construction of parking spaces ..... more details on the scope of this project are covered in the report. In addition, the project profile includes core details such as project name, stage, location,...
-
Product Insights
New![]()
Net Present Value Model: Zealand Pharma AS’s Dapiglutide
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Armata Pharmaceuticals Inc’s APPA-02
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Novo Nordisk AS’s HS-001
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RD-76535958 in Neurodegenerative Diseases
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RD-76535958 in Neurodegenerative DiseasesDrug Details:RD 765.35958Â is under development for the treatment of neurodegenerative diseases.Report CoverageThe data...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-151 in Parkinson’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-151 in Parkinson's Disease Drug Details: DNL-151 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JTC-064 in Neurodegenerative Diseases
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JTC-064 in Neurodegenerative Diseases Drug Details: JTC-064 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Pertussis (Whooping Cough)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine 2 in Pertussis (Whooping Cough) Drug Details:Pediatric DTaP vaccine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Influenza (Pentavalent) Vaccine in Seasonal Influenza
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Influenza (Pentavalent) Vaccine in Seasonal Influenza Drug Details:Vaccine is under development for the prevention of seasonal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-343 in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DNL-343 in Amyotrophic Lateral Sclerosis Drug Details: DNL-343 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-310 in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.DNL-310 in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )Drug Details:DNL-310 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-343 in Frontotemporal Dementia (FTD)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DNL-343 in Frontotemporal Dementia (FTD) Drug Details: DNL-343 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.